Critical Comparison: electroCore (ECOR) vs. Its Competitors

electroCore (NASDAQ:ECOR – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare electroCore to related businesses based on the strength of its earnings, analyst recommendations, dividends, profitability, institutional ownership, valuation and risk.

Volatility and Risk

electroCore has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, electroCore’s peers have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.

Valuation and Earnings

This table compares electroCore and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
electroCore $32.03 million -$13.97 million -3.18
electroCore Competitors $1.90 billion $136.32 million 5.94

electroCore’s peers have higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for electroCore and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
electroCore 1 1 1 0 2.00
electroCore Competitors 4330 10559 18358 840 2.46

electroCore presently has a consensus target price of $18.00, indicating a potential upside of 307.24%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.68%. Given electroCore’s higher probable upside, research analysts plainly believe electroCore is more favorable than its peers.

Institutional & Insider Ownership

26.7% of electroCore shares are owned by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 7.8% of electroCore shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares electroCore and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
electroCore -33.46% N/A -74.21%
electroCore Competitors -191.42% -197.86% -21.83%

Summary

electroCore peers beat electroCore on 10 of the 13 factors compared.

electroCore Company Profile

(Get Free Report)

electroCore is a medical technology company that develops non-invasive bioelectronic therapies. Its products use non-invasive vagus nerve stimulation (nVNS), which delivers gentle electrical stimulation through the skin to activate the vagus nerve. The company’s gammaCore device is used for the treatment of certain headache conditions, including migraine and cluster headache, subject to its regulatory clearances and indications. electroCore also offers Truvaga, a consumer wellness product that uses non-invasive vagus nerve stimulation.

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.